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Immunotoxins as antiviral therapeutics are largely unexplored but have promising prospective due to their high selectivity potential
and their unparalleled efficiency. One recent example targeted the virus-encoded G protein-coupled receptor US28 as a strategy
for specific and efficient treatment of human cytomegalovirus (HCMV) infections. US28 is expressed on virus-infected cells and
scavenge chemokines by rapid internalization. The chemokine-based fusion-toxin protein (FTP) consisted of a variant (F49A) of
CX3CL1 specifically targeting US28 linked to the catalytic domain of Pseudomonas exotoxin A (PE). Here, we systematically seek
to improve F49A-FTP by modifications in its three structural domains; we generated variants with (1) altered chemokine sequence
(K14A, F49L, and F49E), (2) shortened and elongated linker region, and (3) modified toxin domain. Only F49L-FTP displayed
higher selectivity in its binding to US28 versus CX3CR1, the endogenous receptor for CX3CL1, but this was not matched by a more
selective killing of US28-expressing cells. A longer linker and different toxin variants decreased US28 affinity and selective killing.
Thereby, F49A-FTP represents the best candidate for HCMV treatment. Many viruses encode internalizing receptors suggesting
that not only HCMV but also, for instance, Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus may be targeted by
FTPs.
1. Introduction
Immunotoxins constitute a class of protein-based therapeu-
tics and are considered promising anticancer therapies in
the clinic [1, 2]. They are chimeric molecules that consist of
a toxin fused to a targeting moiety. The targeting domain
is most commonly the antigen-binding fragment of a mon-
oclonal antibody but can also comprise receptor ligands,
such as a growth factor or a cytokine that targets specific
cell surface receptors [1]. Pseudomonas exotoxin A (PE) is a
highly toxic protein that has been used to generate several
immunotoxins undergoing evaluation in clinical trials [3–5].
The structure and mechanism of action of PE allow for mod-
ifications so that PE can be converted into an immunotoxin
by changing its target to a different cell surface receptor [6].
PE-based immunotoxins usually contain a fragment of the
Pseudomonas aeruginosa exotoxin A, consisting of domains
II and III of the native toxin, while domain I is replaced
by the targeting moiety. Once the target domain binds to
its receptor, the immunotoxin is internalized by endocytosis,
cleaved in domain II by the proprotein convertase furin,
leading to the release of the toxin and a subsequent cell
killing.
Within the last decades, the potential and success rate of
developing anticancer immunotoxins have been translated to
other indications, such as infectious diseases [1]. Recently,
the first antiviral immunotoxin entered the stage, targeting
the viral G protein-coupled receptor (GPCR) US28 encoded
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by the human cytomegalovirus (HCMV) [7]. The targeting
moiety was not an antibody, but a variant of the chemokine
CX3CL1 optimized for specific binding to US28. Wild- type
CX3CL1 only targets one additional receptor, namely, its cog-
nate receptor, CX3CR1. CX3CL1 is unique among endogenous
chemokine ligands, as it exists in two forms: a soluble form
and a form where the chemotactic chemokine is anchored to
the cell membrane by an extended mucin-like stalk and an
alpha-helix through the membrane [8].
Viral piracy of the endogenous chemokine system is a
commonly used viral strategy to circumvent and/or manipu-
late the host chemokine system and thereby the host immune
response in benefit of virus survival and spreading [9–
11]. Thus, HCMV devotes a significant part of its genome
to immune modulatory gene homologs, including several
predicted 7-transmembrane GPCRs: UL33, UL78, US27, and
US28, with US28 being a functional chemokine G protein-
coupled receptor [12]. Still related to the immune system but
outside the chemokine system, herpesviruses have developed
another strategy to manipulate the host by downregulation
of surface expressed MHC class I molecules, a property
described for the constitutively active GPCR denoted BILF1
by Epstein-Barr virus (EBV) [13–18]. However, most of the
viral GPCRs show homology to the humane chemokine
receptors, for example, the resemblance of US28 to the
human CX3CR1 receptor [9, 12] and the CXC-chemokine
receptors encoded by rhadinoviruses like ORF74 encoded by
humanKaposi’s sarcoma-associated herpesvirus (KSHV) and
of Equine herpesvirus 2 and ECRF3 encoded by Herpesvirus
saimiri [19–22]. In addition, viruses encode chemokine lig-
ands, for example, vCCL1-3 encoded by KSHV [23] and
MC148 from the pox virus molluscum contagiosum [24–26].
A third principle to target the chemokine system by virus is
by scavenging host chemokines by viral chemokine binding
proteins [27].
US28 is a broad-spectrum chemokine receptor yet
binds CX3CL1 with superior affinity as compared to CC-
chemokines [28]. Moreover, it signals with high constitu-
tive activity [29, 30] and undergoes constitutive ligand-
independent receptor internalization [31], a feature well
suited for immunotoxin delivery. Based on the molecular
and pharmacological properties of US28 and the structural
property of CX3CL1, the prototype immunotoxin CX3CL1-
FTP was designed [7]. The chemokine domain of CX3CL1
was chosen as targeting moiety and the mucin-like stalk
of CX3CL1 was replaced by catalytic active domains of PE.
Moreover, as CX3CL1 also binds to the human CX3CR1, a
US28 selective FTP was generated (F49A-FTP) (Figure 1), by
introducing a single pointmutation (Phe49 to Ala) in CX3CL1
[7]. Both FTPs were highly efficient in controlling HCMV
infections in vitro and F49A-FTP provided unparalleled
potency compared to the gold standard ganciclovir in vivo
[7].
These promising results suggest that chemokine-based
FTPs can be developed into therapeutics to treat HCMV-
associated diseases. Here, we investigate if the US28 selective
FTP (F49A-FTP) can be further optimized in terms of
increased selectivity or potency by a systematic approach
modifying the US28-targeting part (i.e., the chemokine), the
catalytic active domains of PE, and alternations in the linker
region.
2. Materials and Methods
2.1. Antiviral Fusion-Toxin Proteins (FTPs). The FTPs were
prepared as described previously [7]. Briefly, the FTP
DNA constructs were cloned into the pET21a(+) vector
(Novagen) and transformed into E. coli BL21(DE3) pLysS
cells (Novagen) for the preparation of inclusion bodies.
Protein expression was induced with 0.5mM isopropyl 𝛽-
D-1-thiogalactopyranoside (IPTG). Cells were ruptured by
sonication in the following buffer: 50mM Tris-HCl pH 8.0,
100mM NaCl, 5mM EDTA, 10 mM MgCl2, 1 mM benzami-
dine, 3mM DTT, 1mM PMSF, and 10 𝜇g/mL DNase I. The
suspension was centrifuged and the pellet was resuspended
and washed twice with 50mMTris-Cl pH 8.0, 300mMNaCl,
0.25% sodium deoxycholate, and 5mM DTT (the second
time without sodium deoxycholate).
2.1.1. Downstream Purification of Recombinant FTPs. 100 𝜇L
denaturation buffer (3M GnHCl, 100mM Tris-Cl pH 8.0,
5mM EDTA, and 5mM DTT) was added to solubilize the
inclusion bodies, followed by incubation and centrifugation.
The inclusion bodies were dialyzed against 1x PBS at 4∘C and
then overnight against 1x PBS containing 0.2mM cystine and
1mM cysteine. The protein sample was added to two sample
volumes of 50mM Tris-Cl pH 8.0 while stirring, followed by
addition of 3 sample volumes of 50mMHEPES pH 7.2, 1mM
CaCl2, and 5mM MgCl2 and confirmation of the mixture
reaching pH 7.2. The sample was filtered and loaded onto a
Source 30Q column equilibrated in buffer A: 50mM HEPES
pH 7.2, 1mM CaCl2, 5mMMgCl2, and 50mM NaCl. Bound
protein was eluted with a gradient from 0 to 40% buffer B;
buffer B is the same as buffer A, but with addition of NaCl
to 1M, and the fractions with the protein of interest were
concentrated. The sample was centrifuged and loaded onto
a Superdex 75PG column, equilibrated in 1x PBS.
2.2. Tissue and Virus Culture. Human lung fibroblasts cells
MRC-5 (ATCCCCL-171) were purchased from the American
Type Culture Collection (ATCC).The stable inducible clones
of US28 and CX3CR1 were kindly provided by Hjortø et
al. (Department of Neuroscience and Pharmacology, Uni-
versity of Copenhagen) [32]. MRC-5 cells were grown at
10% CO-2 and 37∘C in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and 180 units/mL penicillin. The stable clones of inducible
US28 and CX3CR1 HEK-293 cells were grown as previously
described [32].The recombinant ToledoLUC strain was kindly
provided by Dulal et al. (Department of Microbiology and
Molecular Genetics, Rutgers-New Jersey Medical School)
[33]. ToledoLUC virus stocks were propagated using MRC-5
cells and titrated as described previously [33].
2.3. Radioligand Competition Binding Assay. Stable inducible
clones of US28 and CX3CR1 cells were seeded at 10,000
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Figure 1: Selective killing of HCMV infected cells by F49A-FTP. The FTP consisting of the CX3CL1 variant F49A and the catalytic active
domains of PE binds selectively to US28 (1), and the internalization of the FTP is triggered by internalization of F49A binding to US28
(2). The release of F49A is achieved by furin cleavage (3), and the protein synthesis is inhibited by PE, leading to (4) killing of the human
cytomegalovirus (HCMV) infected cells.
cells/well in poly-D-lysine (Invitrogen) coated 96-well tissue
culture plates (Nunc). One day after seeding US28 and
CX3CR1 receptor expression was induced by tetracycline
(Invitrogen; 3,6 ng/mL and 5 ng/mL, resp.) aimed at obtain-
ing 5–10% specific binding of the added radioactive ligand.
One day after induction, cells were assayed by competition
binding for 3 h at 4∘C using 20–70 pM 125I-CX3CL1 as well
as unlabeled ligand 10 pM to 100 nM in 50mM Hepes buffer
pH 7.4, supplemented with 1mM CaCL2, 5mM MgCL2, and
0,5% (w/v) bovine serum albumin (BSA) (binding buffer).
After incubation, cells were washed twice in ice-cold binding
buffer and supplemented with 0,5M NaCl. Determinations
were made in quadruplicate.
2.4. Cell Killing Assay. Stable clones of inducible US28 and
CX3CR1 HEK-293 cells were seeded in poly-D-lysine-coated
48-well tissue culture plates (Nunc) in 300 𝜇L DMEM (Invit-
rogen). One day after seeding US28 and CX3CR1 receptor
expression was induced by tetracycline (0,125 𝜇g/mL and
0,25 𝜇g/mL, resp.). One day after induction, a single dose
treatment was applied with indicated concentrations of the
FTPs (10 pM to 100 nM) and buffer (negative control) and
cells were incubated for 24 h at 37∘C. To estimate cell health,
the cells were incubated with AlamarBlue (Invitrogen) in
DMEM without FBS (10% solution) 300 𝜇L per well, for 4 h
at 37∘C. Data were collected using a Synergy HT plate reader.
Determinations were made in quadruplicate.
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Table 1: Homologous binding experiments testing the binding affinity of the FTPs.
US28/125I-CX3CL1∗∗ CX3CR1/125I-CX3CL1∗∗ Binding selectivity
log IC50 ± SD IC50 [nM] log IC50 ± SD IC50 [nM] CX3CR1 versus US28 (CX3CL1)
CX3CL1-FTP −8.9 ± 0.26 1.3 −7.3 ± 0.45 50 40
K14E-FTP −7.2 ± 0.31 63 −6.2 ± 0.63 631∗ 10
F49A-FTP −7.5 ± 0.59 32 −5.6 ± 0.81 2512∗ 79
F49L-FTP −8.2 ± 0.95 6.3 −5.5 ± 0.36 3162∗ 501
F49E-FTP −6.5 ± 0.07 316 −5.3 ± 0.40 5012∗ 16
F49A-FTP 2 −7.4 ± 0.49 40 −6.9 ± 0.50 126∗ 3
F49A-FTP 3 −7.3 ± 0.64 50 >5,0 —
F49A-FTP 4 −7.6 ± 0.24 25 −6.5 ± 0.21 316∗ 13
F49A-FTP 7 −7.3 ± 0.38 50 −6.6 ± 0.20 251∗ 5
∗IC50 values of the FTPs bound to CX3CR1 have been estimated from a partial curve.
∗∗IC50 value estimated from 3-4 experiments.
2.5. HCMV Luciferase Assay. MRC-5 (ATCC CCL-171) were
seeded in 96-well white tissue culture plates (Nunc) at an
initial cell density of 8000 cells/well and infected the next day
with ToledoLUC (multiplicity of infection of 0,1 [1 out of 10
cells]). The day after, cells were treated with a single dose of
different concentrations of FTPs (10 pM to 1𝜇M) and buffer
(negative control), followed by an incubation for three days
at 37∘C. On day four after infection, media were exchanged
and 100 𝜇L 1x PBS supplemented with MgCl2 and CaCl2 as
well as 100 𝜇L britelite plus reagent (Perkin & Elmer) were
added. Luciferase activity was measured using a Synergy HT
plate reader. Determinations were made in quadruplicate.
2.6. Data Analyses. Data analyses were performed using
Prism version 6.0.1. Data are expressed as means ± SEM.
3. Results
3.1. Modification in the Chemokine Domain to Gain More
Selectivity for US28. Based on affinity determination of 35
variants of CX3CL1 on US28 and CX3CR1, we previously
identified F49A as the CX3CL1 variant with the highest selec-
tivity to US28 versus CX3CR1 (affinity selectivity index of 182
determined as IC50 for CX3CR1 relative to IC50 for US28)
[7]. Two other CX3CL1 variants (K14E and F49L) also turned
out to be selective towards US28 with a selectivity index of
39 and 81, respectively, and both maintained high affinity
for US28 [7]. Based on these results, the two recombinant
CX3CL1 variants were fused to PE to create the new fusion-
toxin proteins: K14E-FTP and F49L-FTP (Figure 2(a)). As the
Ala-substitution of Phe49 resulted in the highest selectivity
index, we further explored this position, by the introduction
of a glutamic acid, and fused this chemokine with the toxin
to create F49E-FTP. The three FTPs were tested for binding
to US28 and CX3CR1 using
125I CX3CL1 as radioligand and
compared to CX3CL1-FTP (the “prototype”) and F49A-FTP
(Figure 2(b)). F49L-FTP maintained high affinity for US28,
as the affinity to US28 was 5 times increased compared to
F49A-FTP (Figure 2(c) and Table 1) [7]. In contrast, F49L-
FTPs affinity to CX3CR1 was low (in the millimolar range),
leading to a selectivity index of 501 (Figure 2(c) and Table 1).
Thus, F49L-FTP displayed a ∼6,3-fold higher selectivity for
binding to US28 relative to CX3CR1 compared to F49A-
FTP. However, when testing the cell killing activity of the
FTPs (Figure 2(d)), F49A-FTP was still more selective in
killing US28- versus CX3CR1-expressing cells with a 513-fold
higher potency on US28- versus CX3CR1-expressing cells,
whereas F49L-FTPwas half as selectivewith a 275-fold higher
potency (Figure 2(e), Table 2). Despite the overall higher
binding affinity to US28 as compared to CX3CR1 of F49L-
FTP, the FTP with the best selectivity profile in killing US28-
expressing cells (F49A-FTP) was chosen as lead candidate for
further optimization of the nonchemokine parts.
3.2. Refinement of the Linker Region with Parts of the Mucin-
Like Stalk of CX3CL1. Three FTPs with an extended linker
were obtained by adding variable lengths of the mucin-like
stalk of CX3CL1 (F49A-FTP-2 [9aa], F49A-FTP-3 [21aa],
and F49A-FTP-4 [41aa]) (Figure 3(a)).The FTPs maintained
high binding affinity to US28 similar to F49A-FTP (Fig-
ure 3(b)) but had a reduced selectivity in their binding affinity
to US28 versus CX3CR1 (Figure 3(c)), as their affinities to
CX3CR1 increased (Figure 3(b)). Furthermore, the three FTPs
had reduced potencies in cell killing of US28-expressing cells
proportional to the length of the added mucin-like stalk
domain (Figure 3(d)). F49A-FTP-3 and -4 with the longest
part of the mucin-like stalk had an up to 3.3-fold lower
selectivity in killing US28- versus CX3CR1-expressing cells
compared to F49A-FTP (Figures 3(d) and 3(e); Table 2).
Taken together, these results show that elongation of the
linker region with parts of the mucin-like stalk decreases the
potency and selectivity of the FTPs compared to F49A-FTP.
3.3. Reducing the Linker Region by Removing Domain II of
Pseudomonas Exotoxin (PE). The furin cleavage site, located
in domain II of PE, is important for cleavage of the cytotoxic
domains of PE from the chemokine part. We designed two
FTPs F49A-FTP-5 and F49A-FTP-6 without domain II and
hence without the furin cleavage site. In F49A-FTP-6, we
inserted an additional three-amino-acid linker (Gly, Gly, and
Ser (GGS)) between the chemokine domain of CX3CL1 and
the Ib/III domains of PE (Figure 4(a)). The F49A-FTP-5
Journal of Immunology Research 5
Table 2: Cell killing activity of the FTPs.
US28 exp. cells∗∗ CX3CR1 exp. cells∗∗ Selectivity
log IC50 ± SD IC50 [nM] log IC50 ± SD IC50 [nM] US28 versus CX3CR1
CX3CL1-FTP −10.6 ± 0.52 0.026 −9.6 ± 0.45 0.25 10
K14E-FTP −10.5 ± 0.25 0.029 −8.0 ± 0.22 11 380
F49A-FTP −10.6 ± 0.24 0.028 −7.8 ± 0.15 14 513
F49L-FTP −11.1 ± 0.41 0.008 −8.7 ± 0.24 2.2 275
F49E-FTP −9.6 ± 0.47 0.27 −7.5 ± 0.30 32∗ 117
F49A-FTP 2 −10.3 ± 0.08 0.051 −7.8 ± 0.30 16∗ 309
F49A-FTP 3 −9.8 ± 0.16 0.15 −7.6 ± 0.20 25∗ 162
F49A-FTP 4 −9.8 ± 0.06 0.17 −7.6 ± 0.30 25∗ 151
F49A-FTP 5 n.a. n.a. —
F49A-FTP 6 −9.5 ± 0.20 0.34 −7.5 ± 0.10 32∗ 93
F49A-FTP 7 −11.3 ± 0.24 0.005 −9.5 ± 0.49 0.35 66
∗log IC50 values are estimated from a partial curve.
∗∗IC50 value estimated from 3–6 experiments.
variant had a reduced antiviral activity, whereas that of F49A-
FTP-6 was unchanged compared to F49A-FTP (Figures 4(b)
and 4(c); Table 3). As selective killing ofUS28-expressing cells
by the FTP is essential in order to minimize unwanted killing
of uninfected host cells expressing CX3CR1, we tested F49A-
FTP-6-mediated killing of US28- versus CX3CR1-expressing
cells. Compared to F49A-FTP, F49A-FTP-6 displayed a
reduced selectivity for killing US28-expressing cells, as it was
∼5.5 times less selective (Figures 4(d) and 4(e) andTable 2). In
summary, the domain II of PE is not essential for the antiviral
activity, yet its removal decreases the selective killing of the
FTPs indicating an altered function of the FTP.
3.4. Elongating the Linker with a Full Catalytic Domains
of PE. As a final step of this study, we investigated if we
could increase the antiviral activity of the FTP by fusion
of the chemokine with the full catalytic active domains
of PE (domains II, Ib, and III) in variant 7, F49A-FTP-7
(Figure 5(a)). This variant lost selectivity by having a much
higher potency (40-fold) in killing CX3CR1-expressing cells
compared to F49A-FTP (Figure 5(b)) and only a slightly
higher potency (5,6 fold) in killing US28-expressing cells.
The FTP was thereby 7,7 times less selective in killing US28-
versus CX3CR1-expressing cells with a selectivity index of
66 compared to 513 for F49A-FTP (Table 2). We further
determined the antiviral activity of F49A-FTP-7 (Figure 5(c))
and consistent with its improved cell killing, it displayed a
higher potency (up to 7,6 times) compared to F49A-FTP.
In summary, changes in the enzymatic domains of PE led
to a higher antiviral activity of the FTPs but also to more
unspecific killing of CX3CR1-expressing cells. Based on the
results, the prototype FPT “F49A-FTP” with the selective
chemokine binding domain and the truncated enzymatic
domains (translocation domains II and Ib) turned out to
be the best FTP to control virus infections and superior
selectivity in killing US28-expressing cells compared to all
tested FTPs.
Table 3: Antiviral activity of the FTPs.
Potency∗
log IC50 ± SEM IC50 [nM]
CX3CL1-FTP −9.3 ± 0.36 0.52
K14E-FTP −8.1 ± 0.09 8.9
F49A-FTP −7.7 ± 0.05 20
F49A-FTP 2 n.a. n.a.
F49A-FTP 3 n.a. n.a.
F49A-FTP 4 n.a. n.a.
F49A-FTP 5 −7.5 ± 0.24 30
F49A-FTP 6 −8.0 ± 0.10 9.3
F49A-FTP 7∗∗ −8.6 ± 0.13 2.6
∗IC50 value estimated from 3–5 experiments.
∗∗IC50 value estimated from 2 experiments.
4. Discussion
In this study, we generated novel FTPs with the attempt to
improve the previously published F49A-FTP [7] in terms
of selective killing of US28-expressing cells and antiviral
activity. In a systematic approach, we first optimize the
chemokine part (that binds to the target receptor). We next
varied the linker part (between the chemokine and the
toxin) and finally the toxin (variations of PE). F49A-FTP was
originally designed based on the selectivity profile (affinity of
US28 versus CX3CR1) of the chemokine part alone, which,
after selection, was fused to the catalytic active domains of
PE (Figure 1) [7]. The chemokine system is characterized
by redundancy and promiscuity with chemokines that bind
more than one receptor and vice versa, but there are also
highly selective andmonogamous receptor : ligand pairs such
as CX3CR1 : CX3CL1 [34]. For CX3CL1 that only binds to one
endogenous receptor CX3CR1 in addition to the viral US28, it
is less complex to employ a rational design strategy to remove
binding to the endogenous receptor CX3CR1 compared to
6 Journal of Immunology Research
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Figure 2: Design, binding, cell killing, and antiviral activity of FTPs with a modified CX3CL1 domain. (a) Schematic representation of
CX3CL1-based FPTs created by fusion of CX3CL1 variants to domains of PE. (b) Binding of the prototype CX3CL1-FTP (grey symbols)
and CX3CL1-based FTPs on HEK-293 cells induced to express US28 (black circles) and CX3CR1 (white squares). (c) Binding selectivity
of CX3CL1-FTP and CX3CL1-based FTPs determined as fold improved affinity for US28 relative to CX3CR1. (d) Cell killing of CX3CL1-FTP
(grey symbols) and CX3CL1-based FTPs on tetracycline induced HEK-293 cells expressing US28 (black circles) and CX3CR1 (white squares).
(e) Selectivity of CX3CL1-FTP and CX3CL1-based FTPs determined as fold improved potency in killing US28- relative to CX3CR1-expressing
cells. Values present IC50 values from 3–5 independent biological replicates (b) and (d).
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Figure 3: Design, binding, and cell killing of FTPs containing parts of the mucin-like stalk of CX3CL1. (a) FTPs with an extended linker
consisting of parts of the mucin-like stalk of CX3CL1. (b) Binding of F49A-FTP and FTPs from this group on HEK-293 cells induced to
express US28 (black circles) and CX3CR1 (white squares). The IC50value for F49A-FTP-3 is >10
−6M (no binding detectable on CX3CR1
expressing cells; marked with a star) and the binding selectivity was therefore not analyzed in (c). (c) Binding selectivity determined as fold
improved affinity for US28 relative to CX3CR1. (d) Cell killing of F49A-FTP and FTPs from this group on tetracycline induced HEK-293
cells expressing US28 (black circles) and CX3CR1 (white squares). (e) Selectivity of F49A-FTP and FTPs from this group determined as fold
improved potency in killing US28- relative to CX3CR1-expressing cells. Values present IC50 values from 3–5 independent biological replicates
(b) and (d).
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Figure 4: Design, cell killing, and antiviral activity of FTPs without domain II and optional with as GS-linker and Ib domain. (a) F49A-FTP
as template for F49A-FTP-5 without domain II between the chemokine domain of CX3CL1 and domain III of PE or for F49A-FTP-6 with an
additional amino-acid linker (GGS) and part of the Ib domain. (b-c) Inhibition of virus replication measured by luciferase activity of MRC-5
cells infected with ToledoLUC (MOI 0,1) and treated once with F49A-FTP (pos. control; dotted line), F49A-FTP-5, and F49A-FTP-6 (black
circles). (d-e) Selectivity of F49A-FTP and F49A-FTP-6 determined as fold improved potency in killing US28- relative to CX3CR1-expressing
cells. Error bars indicate SEM for 3–5 independent biological replicates.
the US28 binding CC-chemokines that interact withmultiple
endogenous CC-chemokine receptors [35, 36]. Importantly,
the unique mucin-like stalk of CX3CL1 is not necessary
for receptor binding as CX3CL1 with this elongation binds
similar to CX3CR1 as the soluble chemokine domain of
CX3C L1 does [37]. For US28, the affinity of CX3CL1 with
its mucin-like stalk is even seven times lower than that of
the CX3C chemokine domain alone [28]. However, as US28
still binds the full length CX3CL1 with high affinity (nM)
[28], this chemokine is suitable for FTP development as the
protein allows for C-terminal modifications and elongations
with maintained US28 recognition (Figure 3(b)). Chemokine
receptor binding is in general facilitated by interactions
between the positively charged chemokine core and the
negatively charged extracellular receptor domains, usually
including the N-terminus [38, 39]. F49A was picked among
35 CX3CL1 variants as the most selective candidate [7]. In the
present study, we chose two other selective CX3CL1 variants
(F49L andK14E), in addition to an extra variant at position 49
(F49E) to create FTPs by fusion of the chemokine fragment
with the Pseudomonas exotoxin fragments and compared
their binding and killing properties to those of F49A-FTP.
F49L-FTP had the highest selectivity index in terms of
binding, yet due to an improved killing of CX3CR1 expressing
cells and maintained high killing of US28-expressing cells,
the selectivity in terms of killing was reduced. Thus, to create
a highly US28-selective FTP as F49A-FTP, it is essential not
only to determine its binding affinity to the target receptor but
also to investigate its specific killing property. A change of the
naturally occurring ligand-receptor complex can influence
the molecular properties of the receptor, for example, the rate
of receptor internalization or its intracellular trafficking, that
is, important receptor features for toxin delivery.
To control HCMV infections, selective targeting of the
infected cells is required, but also a high efficacy of the FTP
to kill cells before the virus spreads is required. Therefore,
we further investigated if we could increase the efficacy of
F49A-FTP by modifying the linker region or the catalytic
active domains of PE. Elongation of the linker region with
parts of the mucin-like stalk of CX3CL1 and also deletion
of domain II of PE reduced the efficacy of the FTPs in
killing US28-expressing cells compared to F49A-FTP. This is
consistent with previous studies where eliminating the furin
cleavage site by deletion or preventing cleavage with a point
mutation in the sites reduced the cytotoxicity of a series of
immunotoxins [40].
Besides changes in domain II, changes in the full catalytic
domains of PE (domains II, Ib, and III) increased the
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Figure 5: Design, cell killing, and antiviral activity of an FTP with full domains of PE. (a) F49A-FTP-7 with full catalytic active domains of
PE. (b) F49A-FTP-7 induced cell killing in comparison to F49A-FTP (dotted line) on tetracycline induced HEK-293 cells expressing US28
(black circles) and CX3CR1 (white squares). (c) Inhibition of virus replication measured by luciferase activity of MRC-5 cells infected with
ToledoLUC (MOI 0,1) and treated once with F49A-FTP (dotted line) or FTPs from this group (black circles). Error bars indicate SEM for 2–5
independent biological replicates.
cytotoxicity and antiviral property of the FTP (F49A-FTP-
7). However, the increased killing was observed in both
US28- and CX3CR1-expressing cells, indicating a generally
improved toxicity of the FTP, again consistent with previous
studies [40]. As selective action towards US28 is a perquisite
to avoid side effects from inadvertent killing of CX3CR1-
expressing cells, the prototype F49A-FTP still presents the
best candidate therapeutic to treat HCMV infections. To
sum up, the presented rational strategy of modifying the
chemokine domain, the linker region, and the cytotoxic
domains did not improve the prototype FTP. However, as
the general understanding of PE toxicity is incomplete, more
knowledge is needed. Moreover, questions remain regarding
the binding and action of F49A-FTP. So far, the binding
of the CX3CL1 variants was tested in competition with
CX3CL1, but it remains to be determined if the modified
CX3CL1 domain of F49A-FTP can compete against the broad
spectrum of CC-chemokines binding to US28, for instance,
in an inflammatory situation. Moreover, it remains to be
described how theCX3CL1-based FTPs act on cells expressing
themembrane boundCX3CL1, as the soluble formof CX3CL1
has been shown to bind to transmembrane CX3CL1 with high
affinity, that is, with the latter acting as a receptor that thereby
influences the communication between cells [41].
Immunotoxins targeting virus-encoded receptors repre-
sent promising drugs, not only forHCMVtherapy but also for
other herpesviruses by targeting their virus-encoded GPCRs.
EBV and KSHV infections can cause cancer and targeting of
their GPCRs could be a novel anticancer treatment strategy.
The broad-spectrum chemokine receptorORF74 fromKSHV
thus seems highly suitable for immunotoxin targeting, as
this receptor (1) can induce the onset of Kaposi’s-like lesions
[42, 43], (2) has a defined chemokine ligand profile [44, 45],
and (3) is internalized in response to human CXCL-1 and
-8 [46]. As such, using immunotoxins designed to target
KSHV-infected cells could be a valid approach to efficiently
kill KSHV-infected cells. With respect to the EBV-encoded
BILF1 receptor, its pronounced cell surface expression [13,
47], constitutive internalization [17], and expression during
the lytic virus replication cycle, but also in latency [48],
indicate that this receptor is a promising drug target suitable
for immunotoxin targeting delivery. A drawback is that EBV-
BILF1 is an orphan receptor (i.e., with no known ligands), but
new technologies including nanobody andmonobody design
could offer highly specific ligands for immunotoxin targeting
of EBV-BILF1. In addition to EBV-BILF1, immunotoxin
targeting of the endogenous receptor EBI2 [49, 50] that
is upregulated upon infection with EBV could be a future
strategy for anti-EBV treatment. The role of EBI2 in the EBV
life cycle is still uncertain [51], but if EBV benefits from high
EBI2 expression, then EBI2 could represent another drug
target to control EBV-associated diseases. However, as EBI2
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is not a viral protein, more side effects would be a risk factor
as the receptor is expressed on a variety of immune cells (B-
cells, T-cells, macrophages, dendritic cells, and many others)
[52–54].
5. Conclusion
Immunotoxin based antiviral drugs offer a novel antiviral
mechanism for combination therapy and for treating infec-
tions that have become resistant to the current first-line inter-
vention. Here, we show that a CX3CL1-based FTP targeting
the HCMV-encoded GPCR US28 can be modified for highly
effective killing of virus-infected cells by modifying the three
structural domains of the FTP (the chemokine domain of
CX3CL1, the linker region, and the catalytic active domains of
PE). By inserting single point mutations in the core domain
of CX3CL1, the FTP loses affinity for CX3CR1, but not for the
virus-encoded receptor US28. Changes in the linker region
do not improve the activity of FTP, whereas changes in the
catalytic active domains of PE increase the killing efficacy for
US28-expressing cells and thereby the antiviral activity.Thus,
CX3CL1-based FTP can be used as scaffold to create highly
efficient and selective FTPs to control HCMV infections. As
several other virus-exploitedGPCRs have been described, the
principle of antiviral therapy targeting these receptors may
not be limited to US28 for the targeting of HCMV but may
be expanded to the targeting of ORF74 for KSHV treatment
and BILF1 and/or EBI2 for the treatment of EBV-mediated
diseases.
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